Literature DB >> 17875580

History-adjusted marginal structural models for estimating time-varying effect modification.

Maya L Petersen1, Steven G Deeks, Jeffrey N Martin, Mark J van der Laan.   

Abstract

Much of epidemiology and clinical medicine is focused on estimating the effects of treatments or interventions administered over time. In such settings of longitudinal treatment, time-dependent confounding is often an important source of bias. Marginal structural models (MSMs) are a powerful tool for estimating the causal effect of a treatment using observational data, particularly when time-dependent confounding is present. In recent statistical work, van der Laan et al. presented a generalized form of MSMs called "history-adjusted" MSMs (Int J Biostat 2005;1:article 4). Unlike standard MSMs, history-adjusted MSMs can be used to estimate modification of treatment effects by time-varying covariates. Estimation of time-dependent causal effect modification is frequently of great practical relevance. For example, clinical researchers are often interested in how the prognostic significance of a biomarker for treatment response can change over time. This article provides a practical introduction to the implementation and interpretation of history-adjusted MSMs. The method is illustrated using a clinical question drawn from the treatment of human immunodeficiency virus infection. Observational cohort data from San Francisco, California, collected between 2000 and 2004, are used to estimate the effect of time until switching antiretroviral therapy regimens among patients receiving a non suppressive regimen and how this effect differs depending on CD4-positive T-lymphocyte count.

Entities:  

Mesh:

Year:  2007        PMID: 17875580      PMCID: PMC2561999          DOI: 10.1093/aje/kwm232

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  7 in total

1.  Marginal structural models and causal inference in epidemiology.

Authors:  J M Robins; M A Hernán; B Brumback
Journal:  Epidemiology       Date:  2000-09       Impact factor: 4.822

2.  Administration of parenteral iron and mortality among hemodialysis patients.

Authors:  Harold I Feldman; Marshall Joffe; Bruce Robinson; Jill Knauss; Borut Cizman; Wensheng Guo; Eunice Franklin-Becker; Gerald Faich
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

3.  Deletion/substitution/addition algorithm in learning with applications in genomics.

Authors:  Sandra E Sinisi; Mark J van der Laan
Journal:  Stat Appl Genet Mol Biol       Date:  2004-08-12

4.  Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

Authors:  Steven G Deeks; Jason D Barbour; Robert M Grant; Jeffrey N Martin
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

5.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen.

Authors:  C Piketty; L Weiss; F Thomas; A S Mohamed; L Belec; M D Kazatchkine
Journal:  J Infect Dis       Date:  2001-03-29       Impact factor: 5.226

6.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.

Authors:  S G Deeks; J D Barbour; J N Martin; M S Swanson; R M Grant
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 7.  Treatment of antiretroviral-drug-resistant HIV-1 infection.

Authors:  Steven G Deeks
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

  7 in total
  22 in total

1.  The impact of unmeasured baseline effect modification on estimates from an inverse probability of treatment weighted logistic model.

Authors:  Joseph A C Delaney; Robert W Platt; Samy Suissa
Journal:  Eur J Epidemiol       Date:  2009-05-06       Impact factor: 8.082

2.  Statistical learning of origin-specific statically optimal individualized treatment rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

3.  Targeted maximum likelihood estimation of the parameter of a marginal structural model.

Authors:  Michael Rosenblum; Mark J van der Laan
Journal:  Int J Biostat       Date:  2010-04-15       Impact factor: 0.968

4.  Petersen et al. Respond to "Effect Modification by Time-varying Covariates"

Authors:  Maya L Petersen; Mark J van der Laan
Journal:  Am J Epidemiol       Date:  2007-11-01       Impact factor: 4.897

5.  On computing standard errors for marginal structural Cox models.

Authors:  R Ayesha Ali; M Adnan Ali; Zhe Wei
Journal:  Lifetime Data Anal       Date:  2013-04-18       Impact factor: 1.588

6.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

Authors:  Miguel A Hernán; James M Robins
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

7.  Comparison of methods for estimating the effect of salvage therapy in prostate cancer when treatment is given by indication.

Authors:  Jeremy M G Taylor; Jincheng Shen; Edward H Kennedy; Lu Wang; Douglas E Schaubel
Journal:  Stat Med       Date:  2013-07-03       Impact factor: 2.373

8.  Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study.

Authors:  Mélanie Prague; Daniel Commenges; Jon Michael Gran; Bruno Ledergerber; Jim Young; Hansjakob Furrer; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2016-07-26       Impact factor: 2.571

9.  Individualized treatment rules: generating candidate clinical trials.

Authors:  Maya L Petersen; Steven G Deeks; Mark J van der Laan
Journal:  Stat Med       Date:  2007-11-10       Impact factor: 2.373

10.  Time-varying effect moderation using the structural nested mean model: estimation using inverse-weighted regression with residuals.

Authors:  Daniel Almirall; Beth Ann Griffin; Daniel F McCaffrey; Rajeev Ramchand; Robert A Yuen; Susan A Murphy
Journal:  Stat Med       Date:  2013-07-19       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.